An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus Infections in High-risk Pediatric Allogeneic Hematopoietic Cell Transplant Recipients

Trial Profile

An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus Infections in High-risk Pediatric Allogeneic Hematopoietic Cell Transplant Recipients

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Brincidofovir (Primary)
  • Indications Adenovirus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms AdAPT; Study 999
  • Sponsors Chimerix
  • Most Recent Events

    • 08 Nov 2017 Status changed from planning to not yet recruiting.
    • 08 Nov 2017 According to a Chimerix media release, this trial is expected to begin by the end of 2017.
    • 09 May 2017 If positive, data from this trial could enable regulatory approval in Europe for oral BCV, according to a Chimerix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top